Matching hallmarks of cancer complexity with N-of-1 precision oncology

Area of Science:

• Oncology
• Genomics
• Clinical Trials

Background:

• Durable cancer control necessitates co-targeting multiple hallmark capabilities, moving beyond single-pathway inhibition.
• Implementing systems-level precision oncology strategies at scale presents significant challenges.

Purpose of the Study:

• To assess the feasibility of N-of-1, molecularly matched multi-drug regimens.
• To determine the relationship between regimen characteristics and patient survival outcomes.

Main Methods:

• Conducting N-of-1 trials for personalized cancer treatment.
• Utilizing molecular matching to guide multi-drug regimen selection.
• Analyzing survival data in relation to matching score, drug number, and dose.

Main Results:

• N-of-1 molecularly matched multi-drug regimens are feasible without traditional phase 1 trials.
• Patient survival demonstrated a linear correlation with the molecular matching score.
• Survival outcomes did not scale with the number of drugs or their dosage.

Conclusions:

• N-of-1 trials offer a viable pathway for personalized, molecularly matched combination therapies.
• The degree of molecular matching is a critical determinant of survival in precision oncology.
• Future treatment strategies should prioritize molecular concordance over empirical dose or drug number escalation.